However, a relative outcome measure of infection risk was reported most frequently for beta-interferon (14 times over 3 studies), and glatiramer acetate and natalizumab (each 12 times over 2 studies); and least frequently for cladribine and teriflunomide (each 0 times). This evidence concerns the gene IFNB1 and infection.